Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing

H. B. Koon, P. Severy, Daniel Hagg, K. Butler, T. Hill, A. G. Jones, T. A. Waldmann, R. P. Junghans

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Humanized anti-CD25 antibody, daclizumab, was applied in a pilot study of 10 patients with CD25(+) leukemias and pharmacokinetic/pharmacodynamic properties were characterized. Two widely held concepts - tumor sink accelerating pharmacokinetics and higher antigen expression correlating with target cell clearance - were supported by this first systematic evaluation of these questions with actual human clinical data. A flexi-dosing regimen was validated for maintaining target drug levels in vivo with a wide range of tumor burdens. Daclizumab induced clearance of peripheral leukemic cells when highly positive for CD25, but durable responses were not obtained. If daclizumab will have a role in antileukemic therapy, it may be in minimal disease settings or as a component of a combination regimen, but only when CD25 expression is high.

Original languageEnglish (US)
Pages (from-to)190-203
Number of pages14
JournalLeukemia Research
Volume30
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Tumor Burden
Leukemia
Antibodies
Pharmacokinetics
Antibodies, Monoclonal, Humanized
Anti-Idiotypic Antibodies
Antigens
Pharmaceutical Preparations
daclizumab
Neoplasms
Therapeutics

Keywords

  • Antibody
  • HAT
  • Humanized
  • Tac

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Koon, H. B., Severy, P., Hagg, D., Butler, K., Hill, T., Jones, A. G., ... Junghans, R. P. (2006). Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leukemia Research, 30(2), 190-203. https://doi.org/10.1016/j.leukres.2005.06.007

Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. / Koon, H. B.; Severy, P.; Hagg, Daniel; Butler, K.; Hill, T.; Jones, A. G.; Waldmann, T. A.; Junghans, R. P.

In: Leukemia Research, Vol. 30, No. 2, 02.2006, p. 190-203.

Research output: Contribution to journalArticle

Koon, HB, Severy, P, Hagg, D, Butler, K, Hill, T, Jones, AG, Waldmann, TA & Junghans, RP 2006, 'Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing', Leukemia Research, vol. 30, no. 2, pp. 190-203. https://doi.org/10.1016/j.leukres.2005.06.007
Koon, H. B. ; Severy, P. ; Hagg, Daniel ; Butler, K. ; Hill, T. ; Jones, A. G. ; Waldmann, T. A. ; Junghans, R. P. / Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. In: Leukemia Research. 2006 ; Vol. 30, No. 2. pp. 190-203.
@article{3cbcc89805c840629abe2fbf5d89b1de,
title = "Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing",
abstract = "Humanized anti-CD25 antibody, daclizumab, was applied in a pilot study of 10 patients with CD25(+) leukemias and pharmacokinetic/pharmacodynamic properties were characterized. Two widely held concepts - tumor sink accelerating pharmacokinetics and higher antigen expression correlating with target cell clearance - were supported by this first systematic evaluation of these questions with actual human clinical data. A flexi-dosing regimen was validated for maintaining target drug levels in vivo with a wide range of tumor burdens. Daclizumab induced clearance of peripheral leukemic cells when highly positive for CD25, but durable responses were not obtained. If daclizumab will have a role in antileukemic therapy, it may be in minimal disease settings or as a component of a combination regimen, but only when CD25 expression is high.",
keywords = "Antibody, HAT, Humanized, Tac",
author = "Koon, {H. B.} and P. Severy and Daniel Hagg and K. Butler and T. Hill and Jones, {A. G.} and Waldmann, {T. A.} and Junghans, {R. P.}",
year = "2006",
month = "2",
doi = "10.1016/j.leukres.2005.06.007",
language = "English (US)",
volume = "30",
pages = "190--203",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing

AU - Koon, H. B.

AU - Severy, P.

AU - Hagg, Daniel

AU - Butler, K.

AU - Hill, T.

AU - Jones, A. G.

AU - Waldmann, T. A.

AU - Junghans, R. P.

PY - 2006/2

Y1 - 2006/2

N2 - Humanized anti-CD25 antibody, daclizumab, was applied in a pilot study of 10 patients with CD25(+) leukemias and pharmacokinetic/pharmacodynamic properties were characterized. Two widely held concepts - tumor sink accelerating pharmacokinetics and higher antigen expression correlating with target cell clearance - were supported by this first systematic evaluation of these questions with actual human clinical data. A flexi-dosing regimen was validated for maintaining target drug levels in vivo with a wide range of tumor burdens. Daclizumab induced clearance of peripheral leukemic cells when highly positive for CD25, but durable responses were not obtained. If daclizumab will have a role in antileukemic therapy, it may be in minimal disease settings or as a component of a combination regimen, but only when CD25 expression is high.

AB - Humanized anti-CD25 antibody, daclizumab, was applied in a pilot study of 10 patients with CD25(+) leukemias and pharmacokinetic/pharmacodynamic properties were characterized. Two widely held concepts - tumor sink accelerating pharmacokinetics and higher antigen expression correlating with target cell clearance - were supported by this first systematic evaluation of these questions with actual human clinical data. A flexi-dosing regimen was validated for maintaining target drug levels in vivo with a wide range of tumor burdens. Daclizumab induced clearance of peripheral leukemic cells when highly positive for CD25, but durable responses were not obtained. If daclizumab will have a role in antileukemic therapy, it may be in minimal disease settings or as a component of a combination regimen, but only when CD25 expression is high.

KW - Antibody

KW - HAT

KW - Humanized

KW - Tac

UR - http://www.scopus.com/inward/record.url?scp=28844471518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844471518&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2005.06.007

DO - 10.1016/j.leukres.2005.06.007

M3 - Article

C2 - 16165209

AN - SCOPUS:28844471518

VL - 30

SP - 190

EP - 203

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 2

ER -